Valeur20202021202220232024Total du passif405.62 M583.06 M678.45 M703.49 M683.1 MTotal des capitaux propres2.21 B2.49 B2.26 B2.24 B2.16 BTotal du passif et des capitaux propres2.62 B3.07 B2.94 B2.95 B2.84 BDette totale—————Dette nette—————
Exelixis, Inc. - Common Stock
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.